PetMedix™ is pleased to announce a collaboration with Zoetis to develop novel, fully species-specific companion animal monoclonal antibody therapeutics (mAbs) using PetMedix’s proprietary transgenic platforms.
Successful performance of first-ever fully canine antibodies in dog trial paves the way for next-generation technology to meet therapeutic needs in fast growing pet health market.
Scientists working in the labs of PetMedix Ltd have recently achieved the successful transfer of more than 4 Mbp of canine antibody DNA into the mouse genome.
Dr Jolyon Martin, co-Founder and Head of Business Development at animal health start-up, PetMedix Ltd, has been named in the Forbes 30 under 30 Europe List for Science and Healthcare 2021.
Boehringer Ingelheim has entered into a partnership with PetMedix. Strengthening partnerships to accelerate innovation and growth is now one of the key elements of Boehringer Ingelheim’s refocused strategy.
PetMedix announces today that it has raised an equity investment from Cambridge Innovation Capital (Cambridge, UK) that will be used to advance its ground-breaking antibody technology platform seeking to bring innovative medicines to companion pets.
PetMedix now has a new home in 12,000 square feet of brand-new laboratory and office space in BioMed Realty’s latest addition to the Babraham Research
PetMedix has been voted best start-up in the global Animal Pharm Awards. The UK-based start-up is developing a new tier of monoclonal antibody therapy for the animal health market. Situated in the heart of the Cambridge biotechnology cluster, 2020 will see the company take up residence in the new Babraham Campus later in the year.